Wang Haozhou, Chen Xiaofeng, You Chao, Wu Ke, Sun Tong
Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Center of Gerontology and Geriatrics, and National Clinical Research Center of Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Front Neurol. 2025 Aug 18;16:1630286. doi: 10.3389/fneur.2025.1630286. eCollection 2025.
Hydrocephalus following intraventricular hemorrhage (IVH) is a complex neurological condition resulting from cerebrospinal fluid (CSF) circulation disruptions due to intraventricular blood entry. This review synthesizes current evidence on pathophysiology, mechanisms, and treatment strategies. Following IVH, erythrocyte lysis releases hemoglobin and iron, triggering oxidative stress and ferroptosis, while thrombin activation, TGF-β1-mediated fibrosis, inflammatory cascades, and ependymal damage collectively contribute to ventricular enlargement. Key animal models elucidate roles of oxidative stress, cytokines, and complement activation in IVH-induced injury. We highlight evolving insights into CSF absorption pathways and blood metabolite interactions, alongside persistent clinical challenges including delayed diagnosis and therapeutic limitations. Experimental approaches such as thrombolytics, iron chelators, and inflammatory inhibitors show preclinical potential but face significant translational barriers: thrombolytics reduced mortality in the CLEAR III trial yet failed to improve functional outcomes or shunt dependence; iron chelation lacks robust clinical validation; and TGF-β1 inhibition yields conflicting efficacy across models. Future research must address the interplay of blood components, inflammatory mediators, and structural damage, prioritizing biomarker discovery and rigorously validated therapeutic innovation.
脑室内出血(IVH)后发生的脑积水是一种复杂的神经疾病,由脑室内血液进入导致脑脊液(CSF)循环中断引起。本综述综合了关于病理生理学、机制和治疗策略的当前证据。IVH后,红细胞溶解释放血红蛋白和铁,引发氧化应激和铁死亡,而凝血酶激活、转化生长因子-β1介导的纤维化、炎症级联反应和室管膜损伤共同导致脑室扩大。关键动物模型阐明了氧化应激、细胞因子和补体激活在IVH诱导损伤中的作用。我们强调了对脑脊液吸收途径和血液代谢物相互作用不断发展的见解,以及包括诊断延迟和治疗局限性在内的持续临床挑战。溶栓剂、铁螯合剂和炎症抑制剂等实验方法显示出临床前潜力,但面临重大的转化障碍:溶栓剂在CLEAR III试验中降低了死亡率,但未能改善功能结局或分流依赖;铁螯合缺乏有力的临床验证;转化生长因子-β1抑制在不同模型中产生相互矛盾疗效。未来研究必须解决血液成分、炎症介质和结构损伤之间的相互作用,优先发现生物标志物并进行严格验证的治疗创新。